Cantor Fitzgerald set a $10.00 target price on Amarin (NASDAQ:AMRN) in a research note issued to investors on Thursday, August 23rd. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently commented on AMRN. ValuEngine cut shares of Amarin from a hold rating to a sell rating in a research note on Thursday, April 26th. BidaskClub upgraded shares of Amarin from a strong sell rating to a sell rating in a research report on Friday, May 4th. Finally, Zacks Investment Research upgraded shares of Amarin from a sell rating to a hold rating in a research report on Monday, May 7th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $8.00.

Shares of AMRN traded down $0.04 during trading hours on Thursday, hitting $2.90. The company’s stock had a trading volume of 5,007,699 shares, compared to its average volume of 3,349,004. The company has a current ratio of 1.43, a quick ratio of 1.13 and a debt-to-equity ratio of -1.25. Amarin has a 52-week low of $2.35 and a 52-week high of $4.60.

Amarin (NASDAQ:AMRN) last posted its earnings results on Wednesday, August 1st. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.03). The firm had revenue of $52.64 million for the quarter, compared to analysts’ expectations of $54.88 million. The firm’s quarterly revenue was up 16.4% on a year-over-year basis. During the same period last year, the firm earned ($0.04) EPS. equities research analysts anticipate that Amarin will post -0.42 EPS for the current fiscal year.

In other news, General Counsel Joseph T. Kennedy sold 26,942 shares of the business’s stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $3.00, for a total value of $80,826.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.08% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Private Advisor Group LLC raised its holdings in Amarin by 81.8% during the 1st quarter. Private Advisor Group LLC now owns 64,293 shares of the biopharmaceutical company’s stock valued at $194,000 after buying an additional 28,929 shares during the last quarter. DRW Securities LLC raised its holdings in Amarin by 45.1% during the 1st quarter. DRW Securities LLC now owns 80,400 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 25,000 shares during the last quarter. Claraphi Advisory Network LLC raised its holdings in Amarin by 637.3% during the 1st quarter. Claraphi Advisory Network LLC now owns 85,309 shares of the biopharmaceutical company’s stock valued at $257,000 after buying an additional 73,738 shares during the last quarter. TD Asset Management Inc. raised its holdings in Amarin by 54.4% during the 2nd quarter. TD Asset Management Inc. now owns 134,207 shares of the biopharmaceutical company’s stock valued at $415,000 after buying an additional 47,300 shares during the last quarter. Finally, GSA Capital Partners LLP raised its holdings in Amarin by 66.3% during the 2nd quarter. GSA Capital Partners LLP now owns 162,800 shares of the biopharmaceutical company’s stock valued at $503,000 after buying an additional 64,900 shares during the last quarter. Hedge funds and other institutional investors own 38.28% of the company’s stock.

Amarin Company Profile

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Read More: NASDAQ Stock Market Explained

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.